<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157938">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732393</url>
  </required_header>
  <id_info>
    <org_study_id>89470</org_study_id>
    <nct_id>NCT01732393</nct_id>
  </id_info>
  <brief_title>Effect of Quercetin in Prevention and Treatment of Oral Mucositis</brief_title>
  <official_title>Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the effect of Quercetin (a natural flavonoid) on prevention of
      and treatment of chemotherapy-induced oral mucositis in patients with blood malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>lower grade of mucositis</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>grade of mucositis due to WHO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of mucositis</measure>
    <time_frame>3 weeks of study tiem span and after trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>duration of mucositis due to Who criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chemotherapy Induced Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>oral quercetin capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral placebo capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in the placebo group received two placebo capsules containing lactose .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral quercetin capsules</intervention_name>
    <description>10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients  were examined every other day for evaluation of  initiation and severity of oral mucositis.</description>
    <arm_group_label>oral quercetin capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>oral placebo capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient under chemotherapy

          -  for  a hematologic malignancy

          -  the hematologist permits the trial on the patient

          -  agreement of patient for participating in the trial

        Exclusion Criteria:

          -  presence pf ANY oral lesion at the beginning of the trial

          -  loss of follow up

          -  use of digoxin and cyclosporine

          -  patient death
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pegah Mosannen Mozafari, assistant professor</last_name>
    <role>Study Director</role>
    <affiliation>Mashhad University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oral Medicine Department of Mashhad dental School</name>
      <address>
        <city>MAshhad</city>
        <state>Khorasan Razavi</state>
        <zip>91735-498</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 4, 2012</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Pegah Mosannen Mozafari</investigator_full_name>
    <investigator_title>assistant professor of oral medicine</investigator_title>
  </responsible_party>
  <keyword>Quercetin</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Mucositis</keyword>
  <keyword>Hematologic  Malignancies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
